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ABSTRACT
Acquired chemotherapeutic resistance of cancer cells can result from a 
Darwinistic evolution process in which heterogeneity plays an important role. In 
order to understand the impact of genetic heterogeneity on acquired resistance and 
second line therapy selection in metastatic melanoma, we sequenced the exomes 
of 27 lesions which were collected from 3 metastatic melanoma patients treated 
with targeted or non-targeted inhibitors. Furthermore, we tested the impact of a 
second NRAS mutation in 7 BRAF inhibitor resistant early passage cell cultures on 
the selection of second line therapies. 
We observed a rapid monophyletic evolution of melanoma subpopulations in 
response to targeted therapy that was not observed in non-targeted therapy. We 
observed the acquisition of NRAS mutations in the BRAF mutated patient treated with 
a BRAF inhibitor in 1 of 5 of his post-resistant samples. In an additional cohort of 5 
BRAF-inhibitor treated patients we detected 7 NRAS mutations in 18 post-resistant 
samples. No NRAS mutations were detected in pre-resistant samples. By sequencing 
65 single cell clones we prove that NRAS mutations co-occur with BRAF mutations 
in single cells. The double mutated cells revealed a heterogeneous response to MEK, 
ERK, PI3K, AKT and multi RTK - inhibitors.
We conclude that BRAF and NRAS co-mutations are not mutually exclusive. 
However, the sole finding of double mutated cells in a resistant tumor is not sufficient 
to determine follow-up therapy. In order to target the large pool of heterogeneous 
cells in a patient, we think combinational therapy targeting different pathways will 
be necessary.
INTRODUCTION
The MAPK pathway, consisting of RAS-RAF-
MEK-ERK, is a highly conserved signaling cascade in 
eukaryotic cells conserved from yeast to humans with 
many vital cellular functions, such as proliferation, 
differentiation, migration, and apoptosis [1]. About one-
third of cancers have a deregulated MAPK pathway, 
either due to overexpression of receptor tyrosine kinases 
(RTKs), increased production of activating ligands, 
activating mutations in RTKs, RAS or RAF or to failure of 
pathway control mechanisms [1]. In cutaneous melanoma, 
deregulation of the MAPK pathway is mainly caused by 
a hyperactive mutation in BRAF (50% of cases) or NRAS 
(15% of cases), highlighting the important role of controlled 
MAPK signaling for melanocyte homeostasis [1, 2]. 
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Targeting a hyperactivated MAPK pathway driven 
by mutated NRAS or BRAF with specific BRAF- and 
MEK inhibitors, increases the median overall survival 
from metastasized melanoma patients from 9 months with 
no therapy to approximately 14 months with successful 
inhibitor treatment [3]. Unfortunately, resistance to 
MAPK inhibition almost invariably develops [4]. Several 
resistance mechanisms have been described so far, which 
can roughly be divided into those that reactivate the 
MAPK pathway by circumventing the inhibitory effects 
of the MAPK inhibitors, or ones that activate alternative 
signaling pathways  [5]. 
In the case of BRAF inhibitors, Shi et al identified 
reactivation of the MAPK pathway (70% of cases), mostly 
in the form of additional NRAS or KRAS mutation (18% 
and 7% of cases, respectively), CDKN2A loss (7% of 
cases), mutant BRAF amplification (19% of cases) or 
BRAF alternative splicing (13% of cases) as the most 
common resistance mechanisms. They also identified 
the PI3K-PTEN-AKT pathway as the second important 
resistance pathway (22% of their post-treatment samples 
contained mutations in PI3K-AKT regulatory genes) [5].
One of the more prevalent mechanisms is an 
additional mutation in NRAS, leading to reactivation 
of the MAPK pathway [6]. However, it has been 
published that NRAS and BRAF mutations are mutually 
exclusive in single cells due to self-induced apoptosis 
by sustained hyper-activation of the MAPK pathway 
[7, 8]. Consequently, resistant tumors of patients that 
contain both mutations concurrently may be comprised 
of several mutually-exclusive subclones with either the 
activating BRAF or NRAS mutations [7]. A recent paper 
showed that both mutations can co-occur in a small 
area (of approximately 10,000 cells) selected by laser 
microdissection [9], although this does not prove that 
the mutations can co-occur within single cells. Likewise, 
although double-mutated NRAS/BRAF melanoma cultures 
have been previously reported, these may still represent 
heterogeneous mixtures of singly-mutated melanoma 
cells [10, 11, 12], or may have arisen artificially through 
in vitro drug treatment and selection experiments [13]. 
Within a patient, various small populations of tumor 
cells (i.e., subclones) evolve during disease progression, 
which exhibit different genotypes and/or phenotypes 
([14, 15, 16]). Due to these different tumor subclones 
within a patient (intra-patient heterogeneity), it is believed 
that diverse resistance mechanisms can co-exist within 
one patient [17, 5]. However, where these resistance 
mechanisms originate from and how they evolve under 
treatment remains poorly understood [6, 11]. 
To better characterize the evolution of intra-patient 
heterogeneity under different treatment regimens, we 
performed exome sequencing on multiple samples from 
3 stage IV melanoma patients (cohort 1) who each 
received a different therapy (BRAF inhibitor (patient  1), 
MEK inhibitor (patient 3) or multi-receptor tyrosine 
kinase (patient 2)) but progressed quickly under treatment.
We used formal phylogenetic methods on tumor DNA 
to model the evolution of intra-patient heterogeneity 
from primary tumors to each individual metastasis for 
the targeted and non-targeted therapies. In addition, we 
could detect the presence of an NRAS mutated subclone 
in 1 of 5 treatment-resistant tumors from the BRAF 
inhibitor resistant patient (patient 1). Single cell clone 
sequencing from the cell culture generated from this 
treatment resistant tumor revealed the co-occurrence of 
a BRAF and NRAS mutation in a single cell. This was 
confirmed in an additional group of 5 patients (patient 4, 
5, 6, 7 and 8, cohort 2) from whom tumors after BRAF 
inhibitor treatment were collected and where cell cultures 
were generated from these tumors and showed secondary 
NRAS mutations. Sequencing of 65 clonal populations 
derived from 4 of these cell cultures showed the presence 
of both activating MAPK mutations in all but one 
subclone. Further in vitro work with these double-mutated 
cell cultures demonstrated sensitivity to BRAF inhibition, 
but heterogeneous responses to downstream MAPK 
inhibition, as well as to PI3K pathway inhibitors and the 
multi-receptor kinase inhibitor Pazopanib.
RESULTS
Tumor-type dependent, intra-patient heterogeneity
We sequenced whole exomes of 27 samples from 
three metastatic melanoma patients (cohort 1) with 
different mutational statuses and different treatments 
(Table 1 and Figure 1A–1F). For all patients we 
performed exome sequencing on all of their samples and 
confirmed their mutational status (BRAFV600E mutated, 
BRAFWT/NRASWT or NRASQ61K mutated for patient 1, 2 
and 3, respectively) (Table 1, Figure 1, Supplementary. 
Table S1). In addition to these driver mutations, we looked 
for other mutated onco- and tumorsuppressor genes: 
in patient 2 we identified a nonsynonymous germline 
mutation in the Melanocortin receptor MC1RV92M and 
in patient 3 a nonsynonymous germline mutation in the 
Microphthalmia-associated transcription factor MITFE318K 
(data not shown). By using EXCAVATOR and CONTRA 
algorithms we detected a high number of copy number 
variations (CNVs) in many chromosomes, with some 
samples exhibiting large losses throughout the genome 
(Figure 1G–1I). 
Whole-exome phylogenetic analysis identifies 
monophyletic evolution of therapeutic resistance
In order to investigate the evolutionary relationship 
between tumor sites within individual patients, we used 
phylogenetic algorithms to group tumor samples based 
on their total single nucleotide variants (SNVs) and copy 
number variations (CNVs) (Figure 2, Supplementary 
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Table S2). As opposed to the phylogenetic tree of 
patient 2 biopsies, the evolutionary trees from patient 1 
and 3 showed monophyletic clades for the post-resistance 
samples (i.e. late metastases), meaning that these 
originated from only one node (Figure 2). However, no 
known and shared mechanism of resistance to BRAF-
inhibitor or MEK-inhibitor treatment could be identified 
(Supplementary Table S2). Confidence is shown by 
bootstrap supports (arrow) which reflects the percentage 
of bootstrap trees also placing the clade at the endpoints 
of that branch. The tree of patient 2 (BRAFWT and NRASWT, 
patient received non-targeted therapy) did not show this 
strong monophyletic clade of late tumor metastases, 
instead the post-resistant samples originated from multiple 
nodes (Figure 2, arrows). Since there might be multiple 
different resistance mechanisms present in one patient, 
we also sought to identify explanatory protein-coding 
changes in any of the post-treatment samples. However, 
no known mechanisms of resistance were identified in 
the exome data of any tumor in the three patients except 
for the NRASQ61K mutation that was present in a cell line 
(MM121224) derived from a resistant metastasis from 
patient 1 (Figure 2).
Resistant subclones are present heterogeneously 
and at low frequencies
In order to determine the origin of this NRASQ61K 
mutation from patient 1 we performed digital PCR as 
well as ultra-deep sequencing on all tumor samples 
(data not shown, and Figure 2D). Only one cell culture 
(MM121224) and one biopsy where the cell culture was 
derived from had an activating mutation in exon 2 of the 
NRAS gene (NRASQ61K), with a range from 5,473× coverage 
of the NRAS exon to 26,416× coverage by next generation 
sequencing (Figure 2D, and Supplementary Table S3). 
No other sample from this patient had this activating 
mutation, suggesting other resistance mechanisms to be 
involved in the metastases of the same patient. Using 
the program deepSNV, a diverse series of other NRAS 
Table 1: Overview table of all the patients mentioned in this manuscript
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coding mutations in exon 2 was present significantly 
in all samples at low subclonal frequencies compared 
to the germline blood reference from the same patient 
(Figure 2D and 2E, Supplementary Table S3). Interestingly, 
the allele carrying the NRASQ61K mutation was only present 
at a frequency of about 6% in early passage cultures of 
the MM121224 cell line from this patient (Figure 2D–2F). 
Two activating MAPK mutations are present in 
single melanoma cells
To determine the frequency of double mutations in 
early passage cultures in general in a larger patient cohort, 
we Sanger sequenced the NRAS locus in all BRAF-mutated 
cell cultures generated from 2013—2015 archived in 
our melanoma biobank [18]. In this way, we identified an 
additional 8 double-mutated cell cultures, derived from 
7 different patients, bringing the total to 9 out of 122 cell 
cultures (7.4%). Of these 9 cell cultures, 7 had an activating 
BRAF mutation at position 600 and a co-occurring activating 
NRAS mutation at position 61 or 12 (Table 1). Two of these 
cell cultures had a BRAF mutation at another position, 
namely one culture contained the double mutation BRAFD594H/
NRASQ61R and one culture had the double mutation BRAFL597R/
NRASQ61R (Data not shown). The BRAFD594H is an inactivating 
mutation, and a double mutation of this sort is already 
described elsewhere [19]. The BRAFL597R is a less prevalent 
activating mutation for which less information is available. 
We therefore decided to focus on the six patients (patients 
in cohort 2, and patient 1 from cohort 1, see Table 1) with 
cell cultures that had a BRAF mutation at position 600 and a 
co-occurring NRAS mutation at position 61 or 12.
Figure 1: Patient cohort (A, D) Patient 1 had a BRAFV600E mutated melanoma, samples were collected pre- and post 
LGX818 (encorafenib) treatment and included the primary tumor (green), two dysplastic nevi (black), two early 
metastases (orange) and 4 late metastases after tumor relapse (red). (B, E) Patient 2 had a melanoma WT for BRAF and NRAS. 
Samples were collected pre- and post non targeted multi RTK inhibitor (pazopanib), and included the primary tumor (green) and five late 
metastases (red). (C, F) Patient 3 had a NRASQ61R mutated melanoma, samples were collected pre-and post MEK162 (binimetinib) treatment 
and included the primary tumor (green), one early metastasis (orange) and three late metastases (red). (G, H, K) Every ring shows the CNVs 
detected of one biopsy, The enlarged regions show a commonly lost region in chromosome 9 which is coding for the tumor suppressor 
CDKN2A. (G) Patient 1, rings from outside to the center represent two nevi in the two outermost circles followed by the primary tumor, the 
two early metastases and finally the late metastases 1 to 4. (H) Patient 2, rings from outside to the center represent primary tumor samples 
1 to 3 and the late metastases 1 to 5. (I) Patient 3, rings from outsided to the center represent the primary tumor samples 1 and 2, one early 
metastases and the late metastases 1 to 3.
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We asked if the double-mutated cell cultures consisted 
of two exclusive populations of cells (one with BRAF and 
another with NRAS mutations), or if both mutations were 
present in single melanoma cells. To distinguish between 
these possibilities, we generated single-cell clones of 
4 double mutated cell cultures (from patients 1, 5, 7 
and 8) and confirmed by Sanger sequencing the presence 
of both BRAFV600E/K and NRASQ61K/H/R or G12A mutations in 65 
independently derived colonies (Table 1). 
Both alleles (mutated and WT) from BRAF and 
NRAS were found to be expressed with Sanger sequencing 
of cDNA and RNA-seq (data not shown). 
Double mutations occur heterogeneously within 
patients after targeted therapy
In order to investigate the evolution of the NRAS/
BRAF double mutated cancer cells within a patient, we 
analyzed tumor DNA for the presence of double mutations 
in all available histological and frozen material from 
patients 4, 5, 6, 7 and 8 before and after BRAF inhibitor 
treatment (Table 1). For patients 4, 5 and 6 we could 
confirm the presence of the additional NRAS mutation in 
the post-treatment samples from which the cell culture 
was derived. In patient 8, we had generated cell cultures 
from Late met 1 and Late met 2. In Late met 1 we could 
detect the BRAFV600E NRASQ61R double mutation, however 
in Late met 2 we could not detect the additional NRASQ61K 
mutation. For patient 7, the histology block corresponding 
to the tumor from which the cell culture was derived was 
no longer available. In patient 4 and patient 8, we could 
also detect the NRAS/BRAF double mutation in additional 
post-treatment metastasese. Interestingly, the NRAS 
mutation could not be detected in any of the pre-treatment 
biopsy samples.
Double-mutant cells have heterogeneous MAPK 
pathway inhibitor and alternative pathway 
responses
In order to gain more insight into the biology of NRAS/
BRAF double mutated cells, we performed viability assays 
with (control) single and double mutated cell cultures under 
MAPK inhibitor treatment.  Double-mutated cell cultures 
from all 6 identified patients were resistant to three different 
BRAF inhibitors (Figure 3A, Table 2). The response to MEK 
Figure 2: Whole-exome phylogenetic trees of patient biopsies. Branch-lengths represent relative distances based on SNVs and 
indels, and the branches are colored according to biopsy type. Maximum likelihood phylogenetic trees are rooted by the blood sample 
for patient 1 (A), patient 2 (B), and patient 3 (C). Node supports are given as bootstra p values, with greater than 50% considered to be 
strong support. (D, E) deep sequencing results of the NRAS exon 2 locus in multiple samples from patient 1. (F) the double BRAFV600E and 
NRASQ61K mutation is present in colonies derived from single cells.
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and ERK inhibitors was heterogeneous. The cell cultures 
MM140906 and MM150850 were resistant to MEK and 
ERK inhibitors, whereas other cell cultures were sensitive 
or partially resistant for one or for both of the inhibitors 
(Figure 3A, Table 2). We also tested the response for different 
inhibitors of the PI3K-AKT pathway, as this pathway is 
often involved in MAPK pathway inhibitor resistance [5], 
and for the multi-RTK inhibitor Pazopanib. Here the cells 
also showed a heterogeneous response, except for the multi-
RTK inhibitor, for which all cell cultures were resistant 
(Figure 3A, Table 2). Therapies combining a MEK 
inhibitor with different PI3K pathway inhibitors worked 
synergistically in all cell cultures, albeit with different 
strengths (Table 2).  As it was previously thought that 
BRAF and NRAS mutations are mutually exclusive due to 
the growth disadvantage of double mutated cells [8], we 
analyzed the proliferation rate of double-mutated cells 
in vitro, compared to single mutated control cell cultures 
(Figure 3B). Although the cell cultures MM121224 and 
MM140307 showed a higher proliferation rate compared to 
the control cell cultures, the other double-mutated cells had 
reduced proliferation rates. 
As a downstream read-out for BRAF and/
or MEK activation, western blot analysis for total 
ERK and phosphorylated ERK was performed in the 
presence of BRAF, MEK, or ERK inhibition. This 
showed that basal pERK levels were mostly higher in 
the double mutated cells compared to the single NRAS 
mutated control cell cultures (but not in MM150423) 
(Figure 3C). Upon treatment with the BRAF inhibitor 
LGX818 (encorafenib), the pERK levels of MM121224, 
MM150423, MM150849 and MM140906 stayed the same 
compared to the untreated control, whereas the levels 
of MM140307, MM150850 and M130903 decreased 
(Figure 3C). Levels of pERK expression upon MEK162 
(binimetinib) treatment decreased in all cell cultures 
except for MM140906. Upon ERK inhibition, pERK 
levels were reduced in all cell cultures. 
When we compared pERK levels and pAKT 
levels between the different double mutated cell 
cultures without treatment, we found that MM140307, 
MM140906, MM150849 and MM150850 expressed 
relatively high levels of pERK, whereas M130903, 
MM150423 and MM121224 express relatively low levels 
(Figure 3D). pAKT expression is relatively constant 
between the different cell cultures, except MM150849, 
which has a relatively high expression (Figure 3D) 
DISCUSSION
Genetic or transcriptional heterogeneity in tumors 
is a major obstacle to obtaining durable responses to 
Table 2: Overview table of the responses of the different double mutated cell cultures on various 
therapies
A + indicates synergism of combination treatment, with ++ and +++ being a stronger effect. A – indicates no synergy. 
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targeted therapy for metastatic melanoma. In order to 
better understand how individual cancer patients respond 
to standard therapies, we conducted multiple-sample, 
whole-exome sequencing from multiple time-points in 3 
patients receiving different therapeutic regimens. 
The sequencing results were used to infer the 
evolutionary relationships between the tumors within 
each patient, and to determine how each therapeutic 
regimen affected the evolution of genetic heterogeneity. 
Unlike previous studies that showed a branching 
evolution of clones subsequent to targeted therapy, 
we could see a strong, well-supported monophyletic 
evolution of metastases following both BRAF and 
MEK inhibitor treatment and relapse with phylogenetic 
analysis [5]. In contrast, patient 2, who received a 
multi-kinase inhibitor (i.e. pazopanib), did not have a 
monophyletic topology of late tumor metastases, which 
is suggestive of genetic drift between the late metastases. 
Despite the monophyletic segregation of late metastases 
in the patient who received the BRAF inhibitor, no known 
genetic mechanism of resistance was shared between 
all sequenced biopsies accounting for the inter-patient 
heterogeneity and subsequent treatment difficulties. 
In fact, the additional activating mutation in NRASQ61K 
found in patient 1 with a BRAF mutation background 
was only present in a single metastasis of patient 1 and 
absent in all other resistant tumor samples from that 
patient. This is consistent with previously published data 
showing heterogeneity in resistance mechanisms within 
individual patients [5]. 
We went on to check if the double mutation could 
also be found in the cell culture obtained from this 
resistant metastasis, and if these mutations occurred in the 
same cell. By isolating and sequencing colonies derived 
from 23 single-cell clones of the resistant late metastasis 6 
from patient 1, we could show for the first time that both 
activating MAPK mutations (NRAS and BRAF) were 
present in a single tumor cell.  
Figure 3: Viability and proliferation assays of double mutated cells. (A) Viability assays of double mutated cells for 
different MAPK inhibitors and inhibitors from the PI3K-AKT pathway as well as a multi-RTK inhibitor. Single mutated control cell 
cultures are M000921 (BRAFV600E) and M010817 (NRASQ61R), indicated in dotted lines. The double mutated cell cultures are indicated 
in solid lines. MM121224 (BRAFV600E, NRASQ61K) derives from patient 1, MM140307 (BRAFV600K, NRASG12A) derives from 
patient 5, MM140906 (BRAFV600E, NRASQ61R) derives from patient 6, MM150423 (BRAFV600E, NRASQ61R) derives from patient 4,  M130903 
(BRAFV600E, NRASQ61H) derives from patient 7, MM150849 (BRAFV600E, NRASQ61R) and MM150850 (BRAFV600E, NRASQ61K) are both derived 
from patient 8. (B) Doubling time of double mutated cells under standard culturing conditions. Single mutated control cell cultures are 
indicated with stars. (C) Western blots showing pERK and ERK levels under MAPK inhibitor treatment in double mutated cell cultures. 
Single mutated control cell cultures are indicated with stars. (D) Westernblot showing pERK and pAKT levels under basic conditions 
(no treatment) in the different double mutated cells.
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In order to confirm our finding, we identified a 
second cohort of BRAF inhibitor resistant patients from 
whom we had obtained a double mutated cell culture. 
In screening 121 cells from our live-cell biobank, we 
could identify an additional 8 cell cultures with double 
BRAF/NRAS activating mutations, bringing the total to 9 
out of 122 cell cultures. By sequencing colonies derived 
from single-cell clones, we confirmed the presence of 
the double mutation in 64 out of 65 colonies. However, 
in our standard biobank protocol we establish cell 
cultures without additional treatment, also when they 
are derived from a therapy resistant patient. Therefore, 
due to selection, this could be an underrepresentation 
of the actual number of double mutated subclones in 
a typical MAPK-inhibitor resistant tumor. Sequencing 
of colonies derived from single cell clones of three 
of these double-mutated cultures confirmed that all 
except for one colony contained both BRAF and NRAS 
mutations, thus confirming the presence of both activation 
mutations in the same cells. Sequencing of the additional 
immunohistochemistry blocks from these patients only 
identified double mutations in the post-treatment samples, 
confirming the finding in patient 1 from cohort 1.
To understand the general resistance mechanisms of 
the double-mutated cells, we conducted viability assays 
with different MAPK inhibitors. The double-mutated cells 
grew in normal culturing conditions, notably without any 
MAPK inhibition, were all resistant to BRAF-inhibitors, 
but showed heterogeneity in their response to MEK or 
ERK inhibition, possibly because of co-existing mutations 
in other pathways. Combination treatment with MEK and 
BRAF inhibitors, as it is now clinical practice, showed 
synergism in MM121224 and M130903, but no synergistic 
or additional effect in the other cell cultures,Suggesting 
that simultaneous or second-line treatment with other 
MAPK-pathway inhibitors might still be effective in 
controlling progression in selected patients, but not in 
all. However, a MEK inhibitor combined with a PI3K, 
AKT or mTOR inhibitor was synergistic in all of the cell 
cultures, albeit with different strength. It has to be kept 
in mind however, as the double-mutated genotype was 
only present in one or two metastases from each patient, 
it is likely not the most important resistance mechanism 
in these patients and the efficacy of these second-line 
or combination treatments in controlling overall tumor 
burden is questionable. Since no common mechanism of 
resistance was found in any patient, it is possible that the 
other resistant tumors activated different pathways.
Except for 1 cell line (MM150423), all double 
mutated cell lines showed higher expression of pERK at 
the basal level compared to the single NRAS mutated cell 
line M010817. However, the basal level of pERK among 
the double mutated cells varied, with relatively high 
expression in MM140307 and MM140906 and relatively 
low expression in MM150423.  It has been argued that 
BRAF and NRAS mutations are mutually exclusive due 
to a growth deficit of double mutated cells, because of 
senescence-inducing high levels of pERK [8]. In our 
experiment, MM121224 and MM140307 grew faster 
than the single mutated control cell lines and MM140906, 
MM150423 and M130903 grew slower, not supporting 
the view the cells with high pERK level grow slower. 
However, in vitro growth behavior might not represent 
in vivo growth, for instance depending on how well the 
cells have adapted to a 2D culture system, what growth 
factors are present or missing in the cell culture medium 
compared to the in vivo situation and how well the immune 
system can control metastasis formation.
The pERK levels in the cell lines under treatment 
of various MAPK pathway inhibitors showed some 
discrepancy with the proliferation assay. Most profound 
was the strong reduction in pERK upon treatment with 
the BRAF inhibitor and MEK inhibitor in MM140307, 
although the cell line was resistant to these two inhibitors. 
We hypothesize that this is due to the very high pERK 
levels in this cell line at baseline, in such a way that even 
a strong reduction compared to baseline does not suffice to 
block the pathway. This would also be true for MM140906 
under ERK inhibitor treatment, although the cell line is 
resistant to ERK inhibition, levels of pERK show a 
decrease compaired to the baseline, but the levels are still 
high. MM150423 pERK levels are relatively low in MEK 
and ERK treated cells, although the cell line is partially 
resistant to these inhibitors. However, the pERK levels in 
the MEK and ERK treated cells do not differ considerably 
from the untreated cells.
In this study, we show that known-resistance 
mechanisms are present at low frequencies and 
heterogeneously within individual patients. Furthermore, 
we show that finding an additional NRAS mutation in a 
tumor sample following BRAF inhibitor treatment could 
indicate the presence of a double mutated subpopulation 
that is not necessarily sensitive to MEK inhibition or ERK 
inhibition, rendering the MEK inhibitor therapy in all 
such cases suboptimal. This study indicates that genetic 
analysis of one tumor biopsy does not fully define the 
resistance mechanism for the whole patient, which has 
important implications for secondary therapy strategies in 
case of primary resistance.
MATERIALS AND METHODS
Patients and sample preparation
Patients were selected after written consent from 
the patient, given through the university biobank program 
according to ethical approval numbers 647 and 800. 
We collected surplus material before and after therapy 
at autopsy. Samples were processed immediately after 
collection to ensure best possible DNA and RNA quality. 
Primary cell cultures were established as described in [18]. 
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Notably, upon generation of cell cultures, all cultures 
were kept under standard conditions without additional 
treatment, even if they were derived from a therapy 
resistant patient.
DNA was isolated from paraffin embedded tissue, 
fresh frozen tissue, cultured cells and PMCs stored in the 
biobank of the institute of Dermatology of the University 
Hospital of Zürich. Germline DNA from PBMCs was 
sequenced for all patients if available as a reference [20]. 
DNA from paraffin blocks was isolated using the 
FFPE DNA isolation kit from Qiagen (QIAamp DNA FFPE 
Tissue Kit #56404) and optimized protocols developed by 
Ultan McDermott at the Sanger institute. Prior to DNA 
isolation, each block was evaluated by a trained dermato-
histopathologist, and punches were made in tumor regions 
to ensure reduced contamination with stromal tissue.
For DNA isolation from non-paraffin embedded 
samples we followed standard DNA isolation protocols 
published earlier.
Library preparation and sequencing 
DNA quality was measured by an Agilent 2100 
Bioanalyzer or Agilent 2200 Tapestation. One to 
three ug of high quality DNA was used to prepare the 
whole exome library using the Agilent SureSelect V4 or V5 
kit. Sequencing was performed on an Illumina Hiseq 2000 
machine in the Functional Genomics Center at University 
of Zürich. For the whole exome sequencing we sequenced 
0.25 lanes per sample, paired-end, with 100 bp reads.
Whole exome sequencing analysis
Bioinformatics analysis was conducted with a 
modified GATK pipeline [21–23]. Quality control was 
done with „FASTQC” [24]. Alignment of the FASTQ 
file to the reference genome “hg19” [25] Lander, Linton 
et al. 2001) and transformation from SAM to BAM 
was done with “BWA” [26]. PCR duplicates were 
marked by MarkDuplicates from “Picard” [22], Local 
realignment around indels with RealignerTargetCreator 
(GATK), realigning with IndelRealigner (GATK), fix 
mate information with FixMateInformation (Picard), 
base quality score recalibration with Baserecalibrator 
(GATK) and PrintReads (GATK). Variant calling was 
done with UnifiedGenotyper (GATK). For annotation of 
the VCF files we used Annovar [27], Samtools [28] and 
Bedtools [29]. For data interpretation we used Microsoft 
Access, Microsoft Excel, Venny [30], ConSet [31] and 
IGV [32, 33].
For copy number analysis we used Excavator [34] 
and Contra [35], results were visualized with Circos [36].
SNVs were filtered according to the following read 
count criteria: A base must have at least four mutant reads 
and at least 10 total reads, if less than 10 total reads, at 
least half of them must be mutated. Also all SNVs with 
a phred-scaled quality score of < 50 were excluded 
from further analysis. A SNV was called somatic if the 
unfiltered blood sample from the same patient did not 
show any mutant read for this position. 
Mutant allele ratios (MAR) were calculated by 
dividing mutant read counts by total read counts for each 
called SNV. Frequencies for these ratios were calculated 
and trendlines were plotted in Excel with the Moving 
Average method (period: 3). To reduce the number of 
false positive SNVs we applied more strict filtering on 
the private SNVs. Quality threshold was raised to a phred 
score of 100, and the SNV needed to have at least 10 total 
reads. Genes that had more than 8 SNVs were excluded.
Deep sequencing of PCR amplicons containing 
NRAS exon 2
DNA of 7 tumor samples (EMG P5 cell culture, 
M121224, 401/II, 404/II, 403, H12.684, H12.12640/1/B) 
were amplified with primers containing a NRAS 
specific sequence (see chapter sanger sequencing), 
adaptor sequences and a unique multiplex-identifier 
(MID) sequence (according to eurofins protocol). Each 
tumor sample analyzed is carrying therefore the adaptor 
sequence and a unique MID sequence. The PCR product 
was gel purified and 200 ng of each amplicon was sending 
for deep sequencing. Amplicons were subjected to Roche 
454 sequencing using emulsions-PCR. Data were analyzed 
using DeepSNV [37].  
Sanger sequencing
After DNA amplification of NRAS and 
BRAF with the following primers: BRAF forward: 
5ʹCTAAGAGGAAAGATG AAGTACTATG reverse: 
5ʹCTAGTAACTCAGCAGCATCTCAG  NRAS forward: 
5ʹGATAGGCAGAAATGGGCTTGA reverse: 5ʹATCAT
CCTTTCAGAGAAAATAATGC using a touchdown 
program going from 60 C to 55 C in 10 cycles, followed 
by 40 cycles at 55 C, the PCR product was diluted 100× 
and send to Microsynth for sequencing. 
Generation of single cell clones and single cell 
clone sequencing
Cells were distributed over 96-well plate, containing 
1 cell per well, via FACS cell sorting or serial dilutions. 
Cells were grown for several weeks under standard 
conditions [18] until visible colonies had formed. Then, 
medium was removed and wells were washed with 
PBS. Colonies were directly lysed in the well, with 
10 ul lysis buffer (2.5% 1 M Tris pH 8.0 (Ambion), 0.1% 
0.5 M EDTA (Sigma-Alderich), 0.25% Tween 20 (Sigma-
Alderich), 1% proteinase K (Qiagen), Aqua dest.), and 
incubated at 55°C for 1 hour, followed by 5 min at 95°C. 
Afterwards, 10 ul 25 mM MgCl2 was added and the total 
volume was devided over 2 PCR reactions for NRAS and 
BRAF Sanger sequencing.
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Cell sorting
Around 1 × 107 melanoma cells were resuspended in 
100 µl FACS buffer (1% FBS, 5 mM EDTA pH 8, 0.01% 
NaN3/ddH2O in PBS). Cells were incubated for 20 minutes 
at 4°C with the following photosensitive antibodies: Anti-
human MCSP-FITC (1:20 dilution) (Miltenyi Biotec 130-
098-794, Bergisch Gladbach Germany) and Anti-human 
Fibroblasts/Epithelial-PE (1:200 dilution) (ABIN319868, 
Aachen Germany). After washing, cells were resuspended 
in 200 µl FACS buffer and sorted using the Aria IIb (BD 
Biosciences, Franklin Lakes, New Jersey, USA).
Phylogenetic analysis
Maximum Parsimony, Bayesian and Maximum 
likelihood (ML) phylogenies were constructed with the 
POSIX-threads version of RAxML v8.0.19 (7). To correct 
for among-site rate heterogeneity using the Γ distribution, 
we used an ascertainment bias correction and a general 
time reversible (GTR) substitution model. Four rate 
categories (ASC_GTRGAMMA model) were used to 
calculate the optimal tree. Node support was evaluated 
with 100 nonparametric bootstrap pseudoreplicates, they 
therefore indicate the percentage of bootstrap trees that 
contained a given internode branch. 
Variants diagnostic for a given clade are defined 
as existing solely in that clade and nowhere else for 
that position. All leaves emanating from the node in 
question must share a variant and all other leaves must 
contain a different character for a variant to be diagnostic. 
Diagnostic variants can therefore also be termed an 
apomorphy.
Cell viability assay
1 × 104 cells were seeded and treated for 
72 hours with different concentrations of either a BRAF 
inhibitor (PLX4032, LGX818 or GSK2118436), a MEK 
inhibitor (MEK162), an ERK inhibitor (SCH772984). 
DMSO treatment was used as a control. After 
72 hours, the medium was removed and fresh RPMI1640 
supplemented with 10% FCS and 8% MTT reagent 
(Sigma, 5 mg/ml in PBS) was added, and the cells 
were incubated at 37°C. After 1 hour, the RPMI1640 
with MTT reagent was removed and 10% SDS (Sigma) 
and 95% isopropanol/ 5% Formic Acid (Sigma) (ratio 
1:1) were added. After 5 min of incubation at 37°C, 
absorbance was measured at 595 nm (reference 620 nm) 
using a microplate reader.
Synergy calculations
Combination treatments and subsequent calculation 
of synergy were carried out according to the method 
from Chou and Talalay, with the compusyn software, 
available at http://www.combosyn.com/index.html. We 
have taken the mean of the raw CI values for the different 
concentration combinations, in order to determine it 
as overall synergistic (CI value < 0.9) or overall not 
synergistic (CI value > 0.9). 
Proliferation assay
5 × 104 cells/ml were seeded per T75 flask. After 
24 hours, 72 hours, 144 hours and 240 hours the cells 
were counted. From the linear growth fase, the doubling 
time was calculated with http://www.doublingtime.com/
compute.php.
Westernblot
Total protein was collected by washing cells twice 
with ice cold PBS and subsequent lysis in RIPA buffer 
(20 mM Tris-HCl (pH 7.5), 1% Triton X-100 (Sigma), 
137 mM NaCl, 10% glycerol and protease inhibitors 
(Roche)). Concentration of the protein was measured 
with the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, 
CA, USA) according to the manufacturer’s protocol. 
SDS-Page was used to separate the proteins, after which 
they were transferred onto a nitrocellulose membrane. 
Membranes were probed with a rabbit anti-pERK 
antibody (Cell Signaling, product nr #4376S), a rabbit 
anti-ERK antibody (Cell Signalling, product nr#9102) 
and a rabbit anti-GAPDH antibody (Abcam, Cambridge, 
UK, product nr ab9385), followed by horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz, 
product nr sc-2030)Bound antibodies were detected using 
chemiluminescence (ECL, GE Healthcare, Chalfont St. 
Giles, UK). Afterwards, band intensity was measured 
using ImageJ software (imagej.nih.gov/ij/) and pERK 
band intensity was corrected for corresponding GAPDH 
band intensity.
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